Chemours Q2 net loss narrows to $274 million; adjusted EPS falls to $0.42
Chemours reported second-quarter 2026 results on August 4, 2026. Net sales were about flat at $1.6 billion, and the GAAP net loss narrowed to $274 million from $380 million, but adjusted EPS fell to $0.42 from $0.61 and adjusted EBITDA declined to $247 million from $260 million. The company continues to expect full-year 2026 adjusted EBITDA of $775 million to $825 million, while its third-quarter adjusted EBITDA guidance of $175 million to $205 million is below the second-quarter level.
Key points
- Net sales of $1.6 billion, down about 1% from $1,615 million a year earlier; volumes fell 4% and price rose 2%
- GAAP net loss attributable to Chemours of $274 million, or $1.81 per diluted share, versus $380 million, or $2.53 per share, a year earlier; the loss includes reserves tied to the EPA and WVDEP settlement, partly offset by a gain on the Kua
- Adjusted EPS of $0.42 versus $0.61 and adjusted EBITDA of $247 million versus $260 million a year earlier
- Third-quarter adjusted EBITDA guidance of $175 million to $205 million; full-year 2026 adjusted EBITDA outlook of $775 million to $825 million unchanged
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.